Activated factor XII type A and B-type natriuretic peptide are complementary and incremental predictors of mortality in patients following admission with acute coronary syndrome

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 8, 2009, Pages 652-660

  Pönitz, Volker ^a,b   Brügger Andersen, Trygve ^a,b   Pritchard, David ^c   Grundt, Heidi ^a,b   Staines, Harry ^d   Nilsen, Dennis W T ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c Axis Shield Diagnostics Ltd   (United Kingdom)

^d Sigma Statistical Services   (United Kingdom)

Author keywords

Acute coronary syndrome; Chest pain; Factor XIIaA; Myocardial infarction; Prognosis; Risk assessment

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 12A; BRAIN NATRIURETIC PEPTIDE; TROPONIN T;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN SECRETION; RISK ASSESSMENT; RISK FACTOR;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; FACTOR XIIA; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TROPONIN T;

EID: 70449560835     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832fa814     Document Type: Article

References (27)

1. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107:2786-2792.
2. Kurachi K, Fujikawa K, Davie EW. Mechanism of activation of bovine factor XI by factor XII and factor XIIa. Biochemistry 1980; 19:1330-1338. (Pubitemid 10038930)
3. Kaplan AP, Austen KF. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971; 133:696.
4. Murano G. The 'Hageman' connection: interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation. Am J Hematol 1978; 4:409-417.
5. Wachtvogel YT, Kettner C, Hack CE, Nuijens JH, Reilly TM, Knabb RM, et al. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation. Thromb Haemost 1998; 80:686-691.
6. Braat EA, Dooijewaard G, Rijken DC. Fibrinolytic properties of activated FXII. Eur J Biochem 1999; 263:904-911.
7. Schousboe I, Feddersen K, Rojkjaer R. Factor XIIa is a kinteically favorable plasminogen activator. Thromb Haemost 1999; 82:1041-1046.
8. Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med 1978; 147:719-729.
9. Discipio RG. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982; 45:587-595.
10. Wiggins RC, Giclas PC, Henson PM. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 1981; 153:1391-1404.
11. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelian cell membranes. Blood 2002; 99:3585-3596.
12. Pönitz V, Brügger-Andersen T, Pritchard D, Grundt H, Staines H, Nilsen DW. Activated factor XII type A predicts long-term mortality in patients admitted with chest pain. J Thromb Haemost 2009; 7:277-287.
13. Müller-Bardorff M, Hallermayer K, Schröder A, Ebert C, Borgya A, Gerhardt W, et al. Improved troponinT ELISA specific for cardiac troponinT isoform: assay development and analytical and clinical validation. Clin Chem 1997; 43:458-466.
14. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine high-sensitivity C-reactive protein methods. Clin Chem 2001; 47:418-425.
15. Rawlins ML, Qwen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005; 123:439-445.
16. De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014-1021.
17. Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41:1264-1272.
18. Omland T, De Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89:463-465. (Pubitemid 34142525)
19. Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004; 147:260-266.
20. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106:2913-2918.
21. De Winter RJ, Stroobants A, Koch KT, Bax M, Schotborgh CE, Mulder KJ, et al. Plasma N-terminal pro-B-Type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am J Cardiol 2004; 94:1481-1485.
22. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108:275-281.
23. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202:271-281.
24. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203:513-518.
25. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrisey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 2006; 103:903-908.
26. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007; 104:6388-6393.
27. Maas C, Govers-Riemslag JW, Bouma B, Schicks B, Hazenberg BP, Lokhorst HM, et al. Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118:3208-3218.